Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial. - Haidar G; Thomas S; Loubet P; Baker RI; Benfield T; Boonyaratanakornkit J; Kiertiburanakul S; Kim AHJ; Longbrake EE; Molina JM; Paredes R; Tucker D; et al. (The Lancet. Infectious diseases, 2025)